Greg Kennelty

Lenalidomide (Revlimid) was found to significantly increase progression-free survival in patients with relapsed/refractory mantle cell lymphoma when compared with investigator's choice of single-agent therapy.

Martee L. Hensley, MD, discusses what lies ahead for the treatment paradigm of uterine leiomyosarcoma

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

Frontline treatment with CPX-351 (Vyxeos) significantly reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary acute myeloid leukemia.

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Tomasz M. Beer, MD, FACP, discusses how having a deeper understanding of the genetic makeup of patients with castration-resistant prostate cancer would open the door to novel treatments, both monotherapy and combination regimens.

Barbara Burtness, MD, discusses the potential for immunotherapy agents in head and neck cancer.

Manish A. Shah, MD, discusses the BRIGHTER trial, which is investigated BBI608 as a second-line treatment for patients with gastric and gastroesophageal junction cancer who already have undergone platinum and fluoropyrimidine-based chemotherapy.